已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

EXTH-23. BICISTRONIC CAR-T CELLS TARGETING EGFR AND IL13RΑ2 MITIGATE ANTIGENIC HETEROGENEITY IN GLIOMA

抗原 嵌合抗原受体 胶质瘤 下调和上调 癌症研究 体内 生物 肿瘤抗原 体外 表皮生长因子受体 受体 免疫疗法 免疫学 免疫系统 基因 遗传学
作者
Nannan Li,Yibo Yin,Jesse L. Rodriguez,Meghan Logun,Logan Zhan,Jiasi Zhang,Zev A. Binder,Zhiguo Lin
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:24 (Supplement_7): vii214-vii214
标识
DOI:10.1093/neuonc/noac209.822
摘要

Abstract Chimeric antigen receptor (CAR)-T cells have had a significant effect in hematological diseases, with a recent study confirming that the cells can last for ten years in vivo. Unfortunately, to date, CAR-T cells have had little effect in solid tumors. One cause of the treatment difficulty is antigenic heterogeneity. Our experience with CAR-T cells in glioblastoma suggests that addressing antigenic heterogeneity may improve the clinical efficacy. Targeting the epidermal growth factor receptor (EGFR) and interleukin 13 receptor subunit alpha 2 (IL13Rα2) individually could lead to tumor control in the short term, but it will be marked by tumor recurrence through antigen loss or downregulation in the long term. This resistance mechanism can be inhibited by combinatorial targeting. To this end, we have designed a bicistronic construct that targets both EGFR and IL13Rα2 simultaneously, to decrease the potential of antigen escape and tumor recurrence. The bicistronic CAR-T cells employ an “OR” logic gate to modify the T cells and kill the tumor cells in vitro and in vivo, in order to retain effectiveness when one target antigen is lost but the second is still present. Our experimental results demonstrate that and validate the safety and possibility of clinical translation. In addition, the efficiency of transfecting T cells with the single bicistronic vector was higher than two single vectors on monovalent CARs. In summary, the bicistronic CAR-T structure is a promising strategy to address the clinical problem of targeting antigenic heterogeneity in solid tumors and potentially level the barriers for targeted T-cell therapy. Educational Objectives: After completion, participants will be able to explain the importance of antigenic heterogeneity in solid tumors in the context of tumor escape. Participants will also be able to identify a strategy to reducing the problem of antigen escape and tumor recurrence through the implementation of bicistronic CARs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
852应助Yiyi采纳,获得10
2秒前
eq582522完成签到,获得积分10
5秒前
黄黄黄完成签到 ,获得积分10
5秒前
钱多多发布了新的文献求助10
6秒前
晓晓完成签到 ,获得积分10
6秒前
you完成签到 ,获得积分10
7秒前
丫丫完成签到 ,获得积分10
8秒前
小二郎应助sci梦采纳,获得10
8秒前
8秒前
王大壮完成签到,获得积分10
9秒前
9秒前
10秒前
亦屿森发布了新的文献求助10
12秒前
zeyin完成签到,获得积分10
14秒前
liweiDr发布了新的文献求助10
15秒前
情怀应助科研的POWER采纳,获得10
17秒前
WLL发布了新的文献求助10
18秒前
19秒前
秀丽黑裤发布了新的文献求助20
21秒前
饱满的半青完成签到 ,获得积分10
22秒前
24秒前
25秒前
杨ang完成签到,获得积分10
26秒前
桃子完成签到,获得积分10
27秒前
30秒前
李兴完成签到 ,获得积分10
30秒前
深情安青应助请先说你好采纳,获得10
30秒前
30秒前
今后应助晴123采纳,获得10
37秒前
研友_nvNAbn发布了新的文献求助10
42秒前
45秒前
lll完成签到,获得积分10
50秒前
威武的薯片完成签到 ,获得积分10
50秒前
隐形曼青应助liweiDr采纳,获得10
51秒前
genomed应助章鱼小丸子采纳,获得10
52秒前
小团月完成签到 ,获得积分10
53秒前
SSY发布了新的文献求助10
54秒前
58秒前
58秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139341
求助须知:如何正确求助?哪些是违规求助? 2790257
关于积分的说明 7794680
捐赠科研通 2446703
什么是DOI,文献DOI怎么找? 1301325
科研通“疑难数据库(出版商)”最低求助积分说明 626124
版权声明 601109